Key stats
- Market cap
- 7.19B
- Open
- —
- Day range
- —
- 52-week range
- $123.00 – $260.19
- Volume
- 14.7K
- Avg volume
- 1.07M
Q3 FY26Beat
Expected$-0.60
Actual$-0.25
AXSM
Axsome Therapeutics Inc$137.31+$1.30+0.95%Price as of Nov 3, 2026, 9:28 AM ET
Earnings
Q2 FY26
Actual$-0.99
Q1 FY26
Actual$-1.26
Q4 FY25
Actual$-0.56
About
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
- Employees
- 925
- Headquarters
- New York, NY